Entrada Therapeutics (TRDA) Proxy filing summary

Voting matters and shareholder proposals

• Corrections were made to the vote requirements for Proposals 2, 3, and 4 regarding ratification of the auditor and amendments to the 2021 Stock Option and Employee Stock Purchase Plans.

• Proposal 2 requires a majority of votes properly cast for and against to ratify the appointment of Ernst & Young LLP as the independent auditor for fiscal year ending December 31, 2026.

• Proposal 3 and Proposal 4 each require a majority of votes properly cast for and against to approve amendments to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan, respectively.

• Abstentions and broker non-votes will have no effect on the outcome of Proposals 2, 3, and 4.

• The board of directors recommends voting “FOR” all three proposals.

Audit committee and external auditor matters

• Ernst & Young LLP is recommended for ratification as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Executive compensation and say-on-pay

• Proposal 3 seeks approval for Amendment No. 1 to the 2021 Stock Option and Incentive Plan, clarifying the voting standard required for approval.